Histone Demethylase



There are two classes of enzymes involved in histone methylation: methyltransferases and demethylases. While methyltransferases are responsible for establishing methylation patterns, demethylases are capable of removing methyl groups not only from histones but other proteins as well. Histone demethylases not only target methylated sites on histone tails but also interact with methylated sites on non-histone proteins, such as p53.

Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chromatin organization and their tight associations with diseases including cancer and mental disorders.

JMJD1A (also named KDM3A) is a demethylasethat removes methyl from histone lysine H3K9. It plays important roles in various cellular processes, including spermatogenesis, energy metabolism, regulation of stem cell and gender display.

Jumonji domain-containing 3 (Jmjd3) has been identified as a histone demethylase, which specifically catalyzes the removal of methylation from H3K27me3.

Histone Demethylase Inhibitors & Modulators

AS8351
(NSC51355)

Cat. No.: HY-100744

Bioactivity: AS8351 is a **KDM5B** inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



CBB1003

Cat. No.: HY-15774

Bioactivity: CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



CBB1003 hydrochloride

Cat. No.: HY-15774A

Bioactivity: CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



CBB1007

Cat. No.: HY-15313

Bioactivity: CBB1007 is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



CBB1007 hydrochloride

Cat. No.: HY-15313B

Bioactivity: CBB1007 Hcl is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



CBB1007 trihydrochloride

Cat. No.: HY-15313C

Bioactivity: CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1).

Purity: 96.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Corin

Cat. No.: HY-111048

Bioactivity: Corin is a dual inhibitor of histone lysine specific demethylase **(LSD1)** and histone deacetylase **(HDAC)**, with a **K_i(inact)** of 110 nM for LSD1 and an IC_{50} of 147 nM for HDAC1.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



CPI-455

Cat. No.: HY-100421

Bioactivity: CPI-455 is a specific **KDM5** inhibitor.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Daminozide

Cat. No.: HY-13643

Bioactivity: Daminozide(DMASA; DIMG; B 995), a plant growth regulator, selectively inhibits the KDM2/7 JmjC subfamily. IC50 Value: Target: KDM2/7 JmjC Inhibition of shoot elongation in dwarf and tall peas by the 1,1-dimethylhydrazide of succinic acid (B-995) was correlated with the inhibition of the oxidation of...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 g, 5 g



DDP-38003 dihydrochloride

Cat. No.: HY-19612A

Bioactivity: DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an **IC_{50}** of 84 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

DDP-38003 trihydrochloride

Cat. No.: HY-19612B

Bioactivity: DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (**KDM1A/LSD1**) with an **IC_{50}** of 84 nM.

Purity: 98.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



GSK 690 Hydrochloride

Cat. No.: HY-117226A

Bioactivity: GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 **(LSD1)**, with a **K_d** value of 9 nM and a biochemical **IC_{50}** of 37 nM.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GSK-J1

Cat. No.: HY-15648

Bioactivity: GSK-J1 is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with **IC_{50}** of 60 nM towards KDM6B.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



GSK-J1 lithium salt

Cat. No.: HY-15648D

Bioactivity: GSK-J1 lithium salt is a potent inhibitor of **H3K27me3/me2-demethylases JMJD3/KDM6B** and **UTX/KDM6A**, with **IC_{50}** of 60 nM towards KDM6B.

Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg



GSK-J2

Cat. No.: HY-15648A

Bioactivity: GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



GSK-J4

Cat. No.: HY-15648B

Bioactivity: GSK-J4 is a potent **H3K27me3 histone lysine demethylase (KDM)** inhibitor, with **IC_{50}**s of 8.6 μM and 6.6 μM against KDM6B and KDM6A, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



GSK-LSD1 Dihydrochloride

Cat. No.: HY-100546A

Bioactivity: GSK-LSD1 Dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (**LSD1**) inhibitor with an **IC_{50}** of 16 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg



GSK2879552

Cat. No.: HY-18632

Bioactivity: GSK2879552 is an orally available, irreversible inhibitor of **lysine specific demethylase 1 (LSD1)**, with potential antineoplastic activity.

Purity: 99.94%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



IOX1

Cat. No.: HY-12304

Bioactivity: IOX1 is the most potent broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases; IC50 for KDM4A/KDM3A is 0.6/0.1 uM. IC50 value: 0.6/0.1 uM(KDM4A/KDM3A)
[1] Target: JmjC KDMs inhibitor IOX1 is the most potent ... against a representative panel of 2OG oxygenases, including..

Purity: 97.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



JIB-04

Cat. No.: HY-13953

Bioactivity: JIB-04 is a pan-selective **Jumonji histone demethylase** inihibitor with **IC_{50}**s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

Purity: 97.95%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



KDM4D-IN-1

Cat. No.: HY-101928

Bioactivity: KDM4D-IN-1 is a new **histone lysine demethylase 4D** (**KDM4D**) inhibitor with an **IC_{50}** value of 0.41±0.03 μM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



KDM5-IN-1

Cat. No.: HY-100422

Bioactivity: KDM5-IN-1 is a potent, selective and orally bioavailable **KDM5** inhibitor with an **IC_{50}** of 15.1 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



KDM5A-IN-1

Cat. No.: HY-100014

Bioactivity: KDM5A-IN-1 is an inhibitor histone demethylases. Target: Histone Demethylase

Purity: 99.76%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



KDOAM-25

Cat. No.: HY-102047

Bioactivity: KDOAM-25 is a potent and selective **KDM5** inhibitor with **IC_{50}**s of 71, 19, 69, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



ML324

Cat. No.: HY-12725

Bioactivity: ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



NCGC00244536

(KDM4B Inhibitor B3)

Cat. No.: HY-101799

Bioactivity: NCGC00244536 is a potent **KDM4B** inhibitor with an **IC_{50}** of 10 nM.

Purity: 98.57%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



NCGC00247743

Cat. No.: HY-112308

Bioactivity: NCGC00247743 is a histone lysine demethylase **KDM4** inhibitor.

Purity: 99.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg



ORY-1001(trans)

Cat. No.: HY-12782T

Bioactivity: ORY-1001 trans is a selective irreversible lysine (K)-specific demethylase 1A (**KDM1A**/ **LSD1**) inhibitor.

Purity: 99.14%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
5 mg, 10 mg, 50 mg, 100 mg



QC6352

Cat. No.: HY-104048

Bioactivity: QC6352 is a potent **KDM4C** inhibitor with an **IC_{50}** of 35 nM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



S 2101

Cat. No.: HY-110277

Bioactivity: S 2101 is a **lysine-specific demethylase 1** (**LSD1**) inhibitor with an **IC_{50}** of 0.99 μM, **K_i** of 0.61 μM and **K_{inact}/K_i** of 4560 M/s.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



Seclidemstat

(SP-2577) Cat. No.: HY-103713

Bioactivity: Seclidemstat (SP-2577) is a potent **LSD1** inhibitor, with a mean IC_{50} of 127 nM.

Purity: 98.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



SP2509

Cat. No.: HY-12635

Bioactivity: SP2509 is a potent and selective antagonist of **lysine specific demethylase 1 (LSD1)** with IC_{50} of 13 nM.

Purity: 99.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



T-3775440 hydrochloride

Cat. No.: HY-103085

Bioactivity: T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase **(LSD1)** inhibitor with an IC_{50} value of 2.1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Tranylcypromine hemisulfate (dl-Tranylcypromine hemisulfate; trans-2-Phenylcyclopropylamine hemisulfate salt)

Cat. No.: HY-B1496

Bioactivity: Tranylcypromine hemisulfate is an irreversible, nonselective **MAO** inhibitor used in the treatment of depression.

Purity: 99.0%
Clinical Data: Launched
Size: 10mM x 1mL in Water,
100 mg



Vafidemstat

(ORY-2001) Cat. No.: HY-112623

Bioactivity: Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (**LSD1**)/ **MAO-B** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg